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tant role in treating that disorder in primary care. We demon-
strate the cost-effectiveness of Escitalopram for Germany 
measured by successfully treated patients. METHODS: A
markov-model over a horizon of 70 days with three markov-
stages (remission, partial response, no response) was con-
structed. Due to the fact that the perspective of the physician was
taken, only costs for medication have been considered. In order
to include therapeutic decisions of physicians in a naturalistic
matter, a survey of 190 GPs and 60 specialists has been 
conducted. RESULTS: Escitalopram has a 30% (GP: 113 vs. 144
€/successfully treated patient, specialist: 123 vs. 163 €/success-
fully treated patient) more favourable cost-effectiveness ratio
compared with Venlafaxin XR. Depending on the setting (GP/
Specialist) the incremental cost-effectiveness ratio is considered
to be 6800–7400€. The lower costs in the GPs model are due to
referrals to specialists, since from the GPs perspective no further
costs occur. CONCLUSIONS: Escitalopram is a cost-effective
alternative to Venlafaxin XR for the treatment of MDD in the
German setting.
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OBJECTIVE: To compare the cost-effectiveness of escitalopram
and sertraline for the treatment of depression based upon a head-
to-head clinical study and published literature. METHODS: A
decision analytical model was created based upon data obtained
from an eight-week clinical study evaluating escitalopram 
and sertraline for the treatment of major depressive disorder. 
The primary outcome of the clinical study was improvement in
depressive symptoms as measured by the Montgomery-Asberg
Depression Rating Scale. The model was constructed from a
payer’s perspective with a six-month time horizon. The clinical
trial allowed dose titration for sertraline in 50mg increments.
The primary outcome for the model was cost per quality-
adjusted life year (QALY). The decision analysis took into
account the rate of adverse drug reactions by drug and dose.
QALY estimates were assigned to various health states and
included depression, adverse events, and treatment failure. Med-
ication costs were obtained from an Internet pharmacy. Costs of
adverse events and treatment failure were obtained from pub-
lished studies. Estimated physician costs were obtained from US
Medicare fee schedules. RESULTS: The estimated six-month cost
was $952 for escitalopram and $1372 for sertraline. The 
estimated QALYs were 0.403 for escitalopram and 0.393 for 
sertraline. The cost/QALY for the two agents was $2362 and
$3494, respectively. Threshold analyses were conducted to deter-
mine variables that inﬂuenced the results. The most important
variable in the model was the cost of treatment failures. In the
primary analysis, the cost of treatment failures was $8141. When
this cost was reduced to $5000, the cost/QALY was $1993 and
$2808 for escitalopram and sertraline, respectively. CONCLU-
SIONS: The results suggest that escitalopram had a lower cost
and resulted in more QALYs. This difference was due mainly to
a lower ADR rates for escitalopram and fewer titrations with
escitalopram.
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OBJECTIVES: 1) To characterize design of drug beneﬁts of SSRI
antidepressants in health plans offered by employers in the
United States; and 2) To determine the effect of raising copay-
ments on compliance rates of SSRI antidepressants. METHODS:
Data comprised beneﬁt information and claims from Medstat’s
MarketScan database for 2000–2003. Beneﬁt information were
compiled from approximately 135 different plans. Any patient
who ﬁlled a prescription SSRI antidepressants in 2000 and was
continuously enrolled through 2001 was identiﬁed. A difference
in difference approach was used to examine the change in the
days supplied and number of claims ﬁlled for an employer that
raised their three tiered co-payments as compared to an employer
that kept constant one tier copayment rates. RESULTS: Three
tier copayment structures were increasingly common among
employers. Most SSRIs fall in tier two although some of the
newer SSRIs are commonly found in tier three. The average
copayment for tier 1 increased from $5.40 to $7.40. The average
copayment for tier 2 increased from $13.60 to $16.80. The
average copayment for tier 3 increased from $25.40 to $31.20.
When the study employer raised their co-payments by 50%, they
experienced a 25% decline in the number of prescriptions per
person ﬁlled (from 5.2 to 3.9 prescriptions) from 2000 to 2001,
while the control employer demonstrated a 20% decline (from
6.0 to 4.8) in the number of prescriptions ﬁlled. Days supplied
fell by 41.3 days or 24% in the employer that raised copayments
and by 36.3 days or 17% in the control employer. CONCLU-
SIONS: Beneﬁt structure and co-pays have trended towards 
3-tier plans with increasing copayments. As such, increasing
copayments may have a negative effect on compliance and 
possibly outcomes.
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Despite the importance of medication adherence in the manage-
ment of depression, adherence rates for antidepressant therapy
are poor. Failure to adhere to pharmaceutical therapy leads to
poor clinical outcomes and increased health care costs. OBJEC-
TIVE: To evaluate the impact of an interventional program on
antidepressant medication adherence. METHODS: This was a
prospective interventional program with retrospective adherence
study using 24-month pharmacy claims database. Medication
adherence measures included length of therapy, median gap, per-
sistence over time, and procession ratio were obtained prior to
and at 18 months post implementation of interventions. Physi-
cian educational interventions included on-site provider educa-
tion, review of The Agency for Healthcare Research and Quality
(AHRQ) guidelines for major depression, newsletter, and case
management. Patient interventions included case managers fol-
lowed up with non-compliant patients by phone for oral coun-
seling, newsletter, incentive programs, and reminder postcards.
RESULTS: A total of 4021 patients were included in the study.
Signiﬁcant improvements were observed at post intervention for
all adherence parameters. The average length of therapy at
outcome measure was 165 days compared to 131 days at base-
line. Persistence over time showed 72% of patients completed
their acute phase therapy (84 days) compared to 60% at base-
line (p < 0.001) and 55% of patients continued their continua-
tion therapy (180 days) compared to 46% at baseline (p <
0.001). The procession ratio over time at 180 days was 0.8, an
improvement of 24% from the baseline. CONCLUSIONS:
Results of our analysis indicated signiﬁcant improvements in
